• Annual growth of 17% is forecast for cannabis extraction market to reach $28.5 billion by 2027
• Pure Extracts Technologies is already operating leading extraction systems from Vitalis and will soon become one of the first companies to have Vitalis’ new Cosolvent Injection System (“CIS”)
• The CIS delivers dramatically faster throughput capacities, even higher-quality cannabis extracts, optimal ethanol cosolvent flow rates and low ethanol usage

Analysts are aligned on the future of the cannabis extraction market, with expectations for years of double-digit compound annual growth rates. The market experts at Grand View Research see 16.6% CAGR for the market to reach $28.5 billion by 2027 (https://ibn.fm/OSkhQ). Market Insight Reports concurs with the trajectory, seeing the market at $26.1 billion in the next six years (https://ibn.fm/L1IsE). Drivers are another common thread, particularly in medical applications where consumers and scientists continue to expand their understanding of all the healthcare uses for the spate of compounds found in cannabis and hemp plants. That’s good news to extraction companies like Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) that get those compounds, called cannabinoids, out of the plant. The methods for extracting cannabinoids vary, as do the end products. Generally speaking, there are three types of products: full-spectrum, distillates and isolates. Full-spectrum products contain all the cannabinoids found in cannabis while distillates offer higher purity of either THC or CBD, depending on the biomass source.  Isolates are made up of only ultra-pure CBD or THC and no other cannabis compounds. Full-spectrum products are the most popular because of what is known as the “entourage effect,” delivered with the full gamut of cannabinoids. For many people dealing with common ailments like anxiety and pain, cannabinoids are becoming a go-to alternative to traditional pharmaceuticals. Pure Extracts this month ordered brand-new technology from Vitalis, a global leader in extraction systems, to stay on the leading edge of the industry as demand increases. The British Columbia-based Company ordered Vitalis’ state-of-the-art Cosolvent Injection System (“CIS”), meaning Pure Extracts will be one of the first companies in the world to receive the innovative system. The CIS is an add-on that enhances Vitalis carbon dioxide extraction systems, including the Q90 (Vitalis’ flagship product) and R200 (Vitalis’ “massive volume” series) systems currently used at Pure Extracts’ facilities (https://ibn.fm/M1aIT). The CIS provides dramatically faster throughput capacities while maintaining the quality of the cannabis and hemp extracts. Furthermore, the Vitalis CIS has been designed to achieve the optimal ethanol cosolvent flow rate ranges for both cannabis and hemp extracts (i.e., THC and CBD), balancing extract quality with efficiency while keeping ethanol usage exceptionally low. To operators, this translates to better product, more product and higher margins. “We are very excited to be one of the first recipients of the Vitalis Cosolvent Injection System,” said Pure Extracts CEO Ben Nikolaevsky in a news release on the order (https://ibn.fm/hfae2). “It will allow us to ramp-up our production much faster than we had anticipated allowing us to offer our customers exceptional value while still producing the same high-quality oil extracts we are known for,” he concluded. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• FingerMotion’s current offerings includes telecommunications products and services, SMS and MMS services, Big Data Insights (Sapientus) and a Rich Communication Services (“RCS”) platform
• The global telecom industry reached $1.74 trillion in 2019 and was forecast to grow at a CAGR of 5% from 2020 to 2027
• The insurtech market was valued at $2.72 billion for 2020 and is expected to grow at a CAGR of 48.8% during the forecast period from 2021 to 2028. FingerMotion’s proprietary platform, Sapientus, is poised to leverage demand for mobile insurance in the Chinese market
• The company’s Rich Communication Services platform will provide additional resources for businesses and brands in China looking to increase their communications networks and leverage 5G technology
• The company’s management team is made up of individuals who are highly experienced in finance and Big Data, including multiple entrepreneurs who have successfully founded their own companies

FingerMotion (OTCQX: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users. Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City. Current Offerings FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

• Telecommunications Products and Services– FingerMotion’s proprietary universal exchange platform, PigeonHole Integration System (“PIS”), offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
• SMS and MMS Services– The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights– FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
• Rich Communication Services (“RCS”)– FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (“IoT”) applications. The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9). In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D). Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities. Management Team Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia. Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (“MIA”) and an Associate Member of the Chartered Institute of Management Accountants, UK (“ACMA”). Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• AmpliTech Group, Inc. receives over $500,000 of orders from a major defense contractor and a leading satellite broadcaster
• AMPG subsidiary, Specialty Microwave, received a $190,000 order from a leading broadcaster
• AMPG also received a $366,000 order from a major defense contractor for the METIS Program
• With increased demand, Amplitech’s backlog has now reached a record $2.2 million

AmpliTech Group (NASDAQ: AMPG, AMPGW), the provider of industry-leading SATCOM Low Noise Amplifier Solutions for the past 18 years, designs and develops top-quality microwave amplifiers using its experience, technical expertise, and superior design knowledge. AmpliTech announced that the company has received orders worth $500,000 from a major Fortune 100 defense contractor and a major satellite and cable TV broadcaster. The company’s subsidiary, Specialty Microwave, acquired in 2019, is a satellite communications (SATCOM) products company. They received a $190,000 order from a leading broadcaster that will use Specialty Microwave’s unique equipment to process satellite ground station signals behind the antennas. Further, AMPG also received a $366,000 order for its premium low noise amplifiers from a major defense contractor in support of the METIS Program (https://ibn.fm/SMVJN). Fawad Maqbool, the CEO and founder of Ampliteh Group, said that the company was very pleased to receive these orders that reflect the rapidly-increasing demand for high-performance products and its expansion into mainstream emerging technology applications. He went on to say that the demand has remained “pent-up” due to the COVID-19 pandemic, and that they expect bookings to increase in the 2^nd half of the year. With the growing demand for the company’s products, AMPG reached a record backlog this year. Amplitech announced that its backlog reached $2.2 million at the end of the Q1 of 2021. Fawad stated that the growing backlog indicates the increasing demand and revenues in the upcoming quarters. To meet the skyrocketing demands, the company is geared towards strengthening its management team and resources as outlined in the S-1 filing and the recent $11 million capital raise by AMPG. Amplitech is well-positioned and equipped with the necessary funds to expand the company’s disruptive technology base, generate increased revenues, and capture greater volumes of its target technology market sectors (https://ibn.fm/liGen). The company’s products cover a frequency range from 50 kHz to 44 GHz, with plans to eventually offer designs up to 100 GHz. AmpliTech also has developed new products for the 5G/6G wireless ecosystem and infrastructure. For more information, visit the company’s website at www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

• Glioblastoma Multiforme (often known simply as GBM) is a fatal, incurable class of brain cancers that usually leaves patients only about 15 months to live once they are diagnosed
• A recent study by the Washington University School of Medicine found that the length of survivability appeared to improve when the standard chemotherapy regimen was given in the morning instead of the evening
• Brain cancer drug developer CNS Pharmaceuticals is also working on a solution to improve the quality of GBM care, seeing hope in its lead drug candidate, Berubicin, which showed promise in a small Phase 1 trial nearly 15 years ago
• One patient from that Phase 1 trial was still alive and cancer-free as of the most recent assessment in November
• CNS expects to begin a larger, multi-center potentially pivotal trial imminently (as well as collaborating on two Polish trials conducted by sublicensee partner WPD Pharmaceuticals), comparing Berubicin’s performance to the chemotherapy drug lomustine in hundreds of patients at nearly 60 oncology centers around the world

A new study recently completed by the Washington University School of Medicine in St. Louis has found that glioblastoma (“GBM”) brain cancer patients receiving the current chemotherapy standard of care had longer survivability rates if they switched from receiving treatments in the evening to receiving the treatments in the morning — encouraging news for patients with the incurable illness, as well as for neuro-oncology researchers attempting to develop improved treatments, including biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP). “In my lab, we were studying daily rhythms in astrocytes, a cell type found in the healthy brain. We discovered some cellular events in healthy cells varied with time of day,” professor of biology Erik D. Herzog, PhD, stated in a Science Daily report on the study Herzog co-authored with professor of pediatrics and of neuroscience Joshua B. Rubin, MD, PhD (https://ibn.fm/TisXR). “Working with Dr. Rubin, we asked if glioblastoma cells also have daily rhythms. And if so, does this make them more sensitive to treatment at certain times?” Herzog said. “Very few clinical trials consider time of day even though they target a biological process that varies with time of day and with a drug that is rapidly cleared from the body. We will need clinical trials to verify this effect, but evidence so far suggests that the standard-of-care treatment for glioblastoma over the past 20 years could be improved simply by asking patients to take the approved drug in the morning.” GBM patients currently have an average 15-month survival rate after diagnosis of the illness. The Washington University study’s benefits were small — those who received the drug in the morning had an overall survival of about 17 months, while those who received it in the evening had an overall survival of about 13.5 months. But scientists hail any potentially significant increase in survivability as a step in the right direction for treating an incurable disease. Furthermore, among a subset of patients with what are called MGMT methylated tumors, the study’s participants who took the drug in the morning averaged overall survival of about 25.5 months compared to 19.5 months — a difference of six months — for those who were medicated in the evening, the study’s authors reported. CNS Pharmaceuticals is working to determine the efficacy of its lead drug candidate, Berubicin, in fighting off glioblastomas. In a small Phase 1 trial completed by another company well over a decade ago, 44 percent of patients saw their disease stabilize or improve. One Berubicin patient emerged cancer-free and as of the most recent medical assessment in November was still alive and still in remission nearly 15 years after the Phase 1 trial (https://ibn.fm/yZACY). CNS now hopes to advance Berubicin to commercial production, with the start of its potentially pivotal clinical trial slated to begin this quarter. The global trial will compare Berubicin’s response to the effectiveness level of established chemotherapy drug lomustine in 243 GBM patients at about 35 clinical sites in the United States (https://ibn.fm/x8Zp2) and 25 more in foreign locations. The company’s sublicensee partner, WPD Pharmaceuticals, will begin a similar Phase 2 clinical trial of Berubicin in Poland during the second quarter, with interim results anticipated by year’s end or early first quarter of 2022. WPD will also launch a Berubicin trial involving pediatric patients sometime later this year — the first significant investigation involving children with malignant gliomas (https://ibn.fm/CjWPj). Anthracyclines as a class of chemotherapy have been used for over 60 years to treat a variety of cancers. … However, historically, anthracyclines have never been used to treat primary or metastatic brain cancers because scientists could not demonstrate that anthracyclines were able to cross the blood-brain barrier and achieve significant levels of activity in the brain,” CNS CEO John Climaco said in a webinar late last year (https://ibn.fm/d2OFK). “Berubicin may change that history because it is the first anthracycline that, based on limited clinical data, appears to cross the blood-brain barrier and achieve drug levels critical for efficacy against central nervous system malignancies.” For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Company will seek approval for name change at Annual General Meeting scheduled for May 10, 2021
• Name change symbolizes company’s resurgence as relevant contender in U.S. cannabis industry.
• Company currently operates seven Chalice Farms dispensaries throughout the Portland area.

Golden Leaf Holdings (CSE: GLH) (OTCQB: GLDFF), a proven, consumer-driven cannabis company in both the medicinal and recreational marijuana market segments, is planning to make an official corporate name change (https://ibn.fm/gVGzW). The company announced that it will be changing its name to Chalice Brands Ltd. at its annual and special meeting (“AGM”), which is slated for May 10, 2021. “With the hard work of the turnaround behind us, we continue to gather momentum and galvanize management behind the Chalice brand,” stated CEO Jeff Yapp. “Our Chalice Farms stores and our Chalice chews are the pride of our business. As we put the Golden Leaf era behind us, this name change serves to symbolize our resurgence as a relevant contender in the U.S. cannabis industry, driven by leadership in our home market of Oregon.” There are currently seven Chalice Farms dispensaries throughout the Portland area. The open, inviting locations are recognized for the enjoyable consumer experience they offer as GLF has focused on creating a welcoming atmosphere, a wide array of compelling products and an invaluable resource for its customers, regardless of their product experience. In addition to offering some of the highest-quality products from third-party companies, Chalice Farms has its own product line: Chalice Chews. This nutritionally enhanced and award-winning fruit edibles line offers a wide range of flavors, from CBD Green Apple, Kiwi Strawberry and Lemon Ginger to Tangerine, Tropical and Acai Berry. Chalice Chews are an ideal option because they offer a wide range of options, including formulations designed to help support the body and mind, recover from a workout, enjoy a natural energetic zip or slide gently into a great night’s sleep (https://ibn.fm/6y2Wo). In addition to obtaining approval for the name change at the next AGM, company officials plan to seek approval for a share consolidation with the objective of bringing outstanding common shares to approximately 65 million. Details of agenda items for the meeting will be included in the management information circular mailed later this month. Company officials have noted that the name change and share consolidation are both expected to receive overwhelming support. For more information, visit the company’s website at www.GoldenLeafHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to GLDFF are available in the company’s newsroom at https://ibn.fm/GLDFF

• 90% of the cystoscopies performed on bladder cancer patients use white light, which cannot always detect cancer margins or tumors that lie flat against the bladder wall. The American Urology Association recommends blue light for cystoscopic procedures involving bladder cancer.
• Imagin Medical’s i/Blue Imaging System(TM) provides the simultaneous, side-by-side display of white light and blue light images, making it easier to visualize cancer margins and flat tumors, potentially resulting in lower recurrence rates
• The company is has transitioned to the manufacturing stage of the i/Blue System with their contract manufacturer, Lighthouse Imaging
• Bladder cancer is the sixth most prevalent cancer in the United States, with approximately 81,400 new cases in 2020 and approximately 17,980 deaths in 2020

Surgical imaging company, Imagin Medical (CSE: IME) (OTCQB: IMEXF), is on the innovative edge of visualizing bladder cancer, aiming to overcome the challenges associated with current imaging techniques. The conventional treatment for bladder cancer is white light cystoscopy that allows doctors to insert a cystoscope equipped with a lens through the urethra to illuminate and examine the outer wall of the bladder. Cystoscopies may be performed for the following reasons:

• Investigation of signs and symptoms of blood in the urine, incontinence, overactive bladder, and painful urination
• Diagnosis of bladder diseases and conditions, s including bladder cancer, bladder stones, and inflammation within the bladder
• Treatment for bladder diseases and conditions when Special tools can pass through the cystoscope to treat specific conditions and/or remove tumors

Even though the American Urology Association recommends using blue light for cystoscopies, 90% are still performed with white light which cannot clearly visualize the margins of tumors that protrude above the bladder wall or those that run flush along the surface. With the use of a contrast agent that causes cancerous growths to fluoresce, blue light cystoscopy enables surgeons to better visualize the margins of tumors above the wall as well as the flat cancerous growths on the surface, In addition, this method has been proven to reduce bladder cancer recurrence. Two downsides to blue light cystoscopy are its steep price tag and the way that the highlighted blue images displayed on the monitor are not in real time, requiring surgeons to manually switch back and forth between the white and blue light images and rely on memory to resect the cancer. In addition, the current method requires hospitals to purchase proprietary endoscopes, rather than use the standard scopes they already own. Imagin Medical’s innovative i/Blue Imaging System combines blue light and the same already FDA approved contrast agent with advanced optics and light sensors, and employs patented ultrasensitive imaging technology to address these limitations. Both white light and blue light images will be in real time and can be displayed side-by-side on the same monitor, eliminating the need to switch back and forth and providing surgeons with more accurate visualization to resect. Additionally, the i/Blue Imaging System can be adapted to most endoscopes on the market, making it unnecessary for hospitals to swap out their equipment, which makes for a highly cost-effective approach. The company has entered the manufacturing stage with FDA-registered contract manufacturer, Lighthouse Imaging. Imagin Medical intends to expand its technology to other procedures in the future, but the primary focus for now is on bladder cancer, the most expensive form of cancer to treat over the lifetime of a patient. According to Verified Market Research, the global bladder cancer market was valued at $3.43 billion in 2018 but is projected to grow at a CAGR of 4.03% and reach $4.71 billion by 2026 (https://ibn.fm/LfWJx). Bladder cancer is the sixth most prevalent cancer in the United States, totaling 81,400 new cases in 2020 and resulting in approximately 17,980 deaths in 2020. Imagin Medical believes its technology has the potential to revolutionize the current standard of care for bladder cancer patients by advancing the efficiency and accuracy of cancer detection and removal, and potentially reducing recurrence rates. For more information, visit the company’s website at www.ImaginMedical.com. NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• DGTL Holdings Inc. subsidiary signed a multiyear software licensing agreement with a digital sports entertainment and gaming giant
• The first marketing campaign focused on the client’s premier sports gaming brands targeting the 2021 NCAA Men’s Basketball Championship that commenced March 2021.
• Based on the success of this campaign, DGTL was awarded a second activation just one week later for a major league sports activation with the PGA Masters
• DGTL recorded $1,253,000 in revenue for the three months ending November 30, 2020 and sales have grown an average of +75% YOY in the last two quarters

DGTL Holdings (TSX.V: DGTL) (OTCQB: DGTHF) is focused on building a full-service digital media, marketing, and advertising software platform powered by Artificial Intelligence (“AI”) for growth-stage digital media, marketing, and advertising software technology companies. Their goal is to build a portfolio of content, measurement and distribution-based software technologies in the high growth categories social media, gaming, streaming and web advertising. The company recently reported that its wholly-owned subsidiary, Hashoff LLC, has signed a new campaign activation contract with the leading digital sports entertainment and gaming technology company. The client is a top sponsor for a numerous major league sports organizations including; the NBA, NFL, PGA, MLB, NHL and NCAA as well as Nascar, UFC, etc. This client joins a list of global brand juggernaut customers, including Amheuser Busch, Dunkin Brands, Syneos Health, Dentsu, Publicis, Shein, and many others. With these first two major activations, this SaaS licensing agreement includes additional social media marketing strategies for other major sporting events during the two-year term. The first campaign focused on the client’s premier sports gaming brands at the 2021 NCAA Men’s Basketball Championship – “March Madness”, which runs from March 14 to April 5, 2021. The client will leverage Hashoff’s video-based social media content management software to source and manage the top sports agencies, with the goal of driving greater online traffic and engagement on their sports gaming applications. Based on the successful completion of this campaign, the client awarded a contract to cover their brand at the PGA Masters tournament beginning on April 8th, 2021. The Nasdaq listed client, with a market value of over $25 billion, is a global leader in developing and marketing fantasy sports and mobile sports betting applications that enable users to bet on sports-related contests, tournaments, or fantasy sports leagues (https://ibn.fm/IkcPS). Earlier, DGTL Holdings Inc. announced its financial results for the three and six-month periods ending November 30, 2020, representing Q2 and YTD results for FYE 2021.

• DGTL recorded $1,253,000 in revenue for the three months ending November 30, 2020.
• Hashoff recorded a 70% growth in revenue at $738,000 for the same quarter in 2019.
• Compared to DGTL’s revenue of $1,352,000 for the semi-annual period in 2019, the company recorded $2,416,000 for the six months ending November 30, 2020, representing a 79% growth in revenue.
• DGTL Current 2020 calendar year revenue through November 30, 2020, is $3,740,000, compared to $2,320,000 during the same period in 2019, showcasing a growth rate of 61%.

The company attributes the revenue growth to the implementation of DGTL’s three-year revenue growth plan and Hashoff’s exemplary services. Hashoff is fast gaining ground as a leading social media CMS with the surging market demand for CaaS (content-as-a-service) platforms (https://ibn.fm/BL66p). For a multimedia video on Hashoff’s platform at https://ibn.fm/qbHIC For more information, visit the company’s website at www.DGTLInc.com. NOTE TO INVESTORS: The latest news and updates relating to DGTHF are available in the company’s newsroom at https://ibn.fm/DGTHF

• Splash board members boast diverse, extensive leadership experiences in array of industries.
• Board members have served for decades in key roles related to successful growth of Splash.
• Splash Beverages operates in both alcoholic, nonalcoholic beverage segments.

The impact leaders have on organizations is almost impossible to measure — yet they are critical components of a company’s success. Splash Beverage Group (OTCQB: SBEV), a holding company of leading portfolio of beverage brands, blend of essential vitamins, minerals and electrolytes, is committed to building a leadership team — including stellar board members — with the expertise and insight necessary for the company’s growth in the trillion-dollar global beverage industry. Most recently, Splash Beverage announced the appointment of Peter McDonough as an independent board member (https://ibn.fm/2EZXw). McDonough has an unparalleled C.V. for sitting on the board of an upstart company, and he brings incomparable marketing experience to Splash, the company noted, when making the announcement. “We are lucky to be adding Peter to our board,” said Splash Beverage CEO Robert Nistico. “Over the course of his 30-year career, Peter has created successful marketing campaigns and built organizational capabilities that accelerated the growth of business enterprises ranging from small start-ups as well as multi-billion-dollar companies. Peter’s wealth of experience and insights gained while serving as Diageo’s North American president overseeing brand marketing and product development, as well as his vast professional network will be invaluable to Splash’s board of directors. His strategic insights offer helpful counsel as Splash accelerates the growth of our existing brands, TapouT Beverage and Salt Tequila, while adding new brands and expanding our distribution footprint into international markets.” McDonough has garnered diverse and deep leadership experiences in industries such as personal care products, alcoholic beverages, consumer appliances, power tools and bioscience technology. He currently serves as CEO of Trait Biosciences and previously served in senior executive roles at Diageo, Procter & Gamble, Gillette, Duracell and Black & Decker. At Diageo, McDonough acted as president as well as chief marketing & innovation officer. Under his expert guidance, the company launched more than 40 new products in less than a decade, resulting in more than $800 million in cumulative sales and the company’s consistent appearance in the industry’s annual (IRI/Nielsen) list of top-selling new products. Other outstanding Splash Beverage board members include Nistico, who is a board member in addition to serving as Chairman & CEO; and Justin Yorke. Boasting almost three decades of experience in the beverage industry, Nistico was named Splash CEO and a member of the board of directors since inception. Prior to that, he served as Senior Vice President and general manager at Red Bull North America, where he was the fifth employee hired. Nistico was instrumental in building the Red Bull brand in North and Central America as well as the Caribbean. He’s also held key leadership positions at Diageo (formerly I.D.V./Heublein), Republic National (formerly the Julius Schepps Company) and the E&J Gallo Winery. Yorke is a member of the board of directors and, in March of last year, was also named secretary for the company. With more than two decades of experience in finance — including almost half of that in Hong Kong — Yorke has managed funds for a private Swiss bank as well Peregrine Investments and Unifund, a high-net-worth family based in Switzerland. For the past ten years, Yorke has been a partner in San Gabriel Advisors and is the manager of the San Gabriel Fund, JMW Fund and Richland Fund. Specializing in manufacturing, distributing, sales and marketing of various beverages across multiple channels, Splash Beverages operates in both the alcoholic and nonalcoholic beverage segments, allowing it to leverage efficiencies and dilute risk. The company’s business strategy is to quickly develop and accelerate pre-existing brands to exit for cash events. The company’s management team has invaluable expertise and insight, and the company strives to identify brands it perceives to have highly visible preexisting brand awareness or pure category innovation. Specifically, the company looks for brands and products that are on trend and deliver natural quality, health benefits, freshness and refreshment within their beverages. SBEV looks to maintain highest performance standards and focus on execution as it works with distributors and retail partners achieve and exceed all goals. In addition, the company offers support for members of the U.S. armed forces, first responders and health-care professionals. For more information, visit the company’s website at www.SplashBeverageGroup.com. NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

• The novel coronavirus has spawned a number of health-preserving policies, including growing use of remote workplace models to keep employees from close contact with each other
• Lone workers without the immediate physical support of their colleagues may face heightened vulnerability to outside threats, however
• Company facilities may also face heightened vulnerability because of skeleton crew reductions
• Autonomous security robots (“ASRs”) such as those developed by Knightscope can help reduce vulnerabilities through property patrols at the workplace and in public places ranging from parks to parking garages

Autonomous security robot (“ASR”) visionaries at Knightscope are advancing their mission to “make the United States of America the safest country in the world” by producing solutions that don’t sleep, don’t fall ill during a pandemic, and don’t succumb to performance-inhibiting factors such as boredom when things appear to be relatively quiet. Knightscope’s ASR sentries are a friendly, weaponless presence serving clients ranging from the private sector to federal government, proving its use not through interdiction but through detection and allowing its human security partners to determine where to take things from there. The ASRs’ detection capabilities cover a wide range of potential — monitoring signal transmissions that might communicate the launch of a physical threat, heat sources that might indicate a fire still in embryo, human presences that are unexpected or unauthorized, and specific identification features that might be used as clues to solve criminal cases, for example. The Las Vegas Review-Journal recently reported the company’s success in serving a metropolitan apartment complex with a history of significant criminal activity, noting that the complex has become “a quieter, more peaceful place to live” since a Knightscope ASR was deployed there last fall and helped reduce the incidence of crime and vandalism (https://ibn.fm/oCj0D). Security concerns are as pressing as ever in the era of the COVID pandemic, when companies are relying heavily on distributed workforce models that help employees maintain their health and wellbeing by working from a remote base outside the office. Trade magazine Security recently observed that the pandemic has created more “lone workers” than ever, defined as “individuals who work alone without close or direct supervision, and are often more vulnerable to risks that many office-based workers may not experience.” The magazine commented that, “Organizations in charge of protecting lone workers must fulfill their duty of care, taking all steps reasonably possible to ensure the safety, well-being and physical and mental health of their employees,” with the consequence of inaction being that critical employees may become vulnerable to harm and leave the company itself vulnerable to harm as well (https://ibn.fm/HRREQ). Those vulnerabilities can occur at the remote locations, where workers may find themselves exposed to dangerous influences without having other supportive staffers nearby to provide help, or at the company’s physical facilities, where a skeleton crew of employees may be unable to sufficiently respond to an attack on the business’s infrastructure, Security states. Understaffed security forces have “been forced into lone worker scenarios and are suffering from a lack of support resources. They cannot just watch people as they used to, as they’re tasked to do an impossible job of dealing with guest requests, front desk work by checking people in and out, while still responsible for overseeing perimeter security and the monitoring of visitors,” Karl Perman, president and co-founder of risk consultancy CIP CORE, told the magazine. Perman suggested that organizations can’t afford to operate under the same security program that existed before the COVID-19 outbreak. One potential solution is Knightscope’s range of autonomous robot sentries, which currently have been deployed in three types of models — one that is stationary within the office complex, one equipped to rove the office building with obstacle avoidance a part of its basic programming, and a third that is capable of patrolling the property outside the office complex. “A violent crime occurs every four seconds and a property crime every 25 seconds. … Crime has more than a trillion-dollar negative economic impact on the U.S. every single year,” Knightscope founder and CEO William Santana Li says in a recent YouTube video about him and the company (https://ibn.fm/QiMpO), adding in another video, “Each (Knightscope robot) proudly displays the stars and stripes, signifying our patriotic duty to our country” (https://ibn.fm/oNWic). Knightscope has exceeded 20,000 investors since rolling out its first autonomous product in 2015, utilizing a Reg A+ offering that allows Knightscope to attract private investments without establishing a public IPO (https://ibn.fm/kzbP9). For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Cybin has completed more than 20 pre-clinical studies in record time.
• Company is advancing two new therapeutic candidates with enhanced, improved properties.
• Drug candidates are designed to treat serious psychiatric conditions with high unmet medical needs.

Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, has completed key research studies both in vitro and in vivo. The company recently announced that it had completed its 20th pre-clinical study and had progressed two psychedelic investigational new drug candidates: CYB003 and CYB004 (https://ibn.fm/jDvFz). The studies were completed in record time, the company reported, in part because of close collaboration with its partners and contractors. “Excellent teamwork and fully supportive partners have greatly facilitated the advancement of these two new therapeutic candidates with enhanced and improved properties,” said Cybin chief R&D officer Michael Palfreyman. “We look forward to rapid progress towards clinical studies.” The completed studies were focused on evaluating proprietary Cybin technologies, and more than 20 definitive research studies designed by the Cybin scientists were conducted. Results of the studies have led to the progression CYB003 and CYB004, two proprietary psychedelic therapeutics which have entered into full IND-enabling studies. These studies are in preparation for upcoming clinical testing designed to analyze the effectiveness of these therapeutics in the treatment of serious psychiatric conditions with high unmet medical needs. The company has also initiated an API manufacturing contract with a strategic pharmaceutical manufacturing partner. According to Cybin, the pre-clinical studies of CYB003 and CYB004 candidates included API synthesis and optimization to prove that the two psychedelic molecules show significant in vivo modifications of pharmacokinetics consistent with proof of concept. These two studies are only a part of Cybin’s impressive pipeline. Currently the company is developing more than 50 proprietary psychedelic molecules and multiple proprietary delivery mechanisms and supportive technology platforms. The company plans to continue to progress its novel next-generation psychedelics based on well-known scaffolds including psilocybin, DMT, MDMA with improved bioavailability and optimized pharmacokinetic profiles to provide shorter duration of action with the potential for reduced side effects. “Our internal research and development team, along with an extensive network of partners, has progressed CYB003 and CYB004 into IND-enabling studies at an impressive pace,” said Cybin CEO Doug Drysdale. “I am in no doubt we have the best team in this sector and the right team to progress these exciting future treatments into clinical studies over the next 12 months.” Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug- discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN